Neonatal Congenital Syphilis: Screening and Treatment Updates

Congenital syphilis remains a preventable cause of fetal loss, stillbirth, prematurity, neonatal illness, and long-term disability. It develops when Treponema pallidum crosses the placenta during pregnancy, although transmission can also occur through contact with infectious lesions during birth. Rising rates of syphilis among reproductive-age adults have made prevention a renewed priority for obstetric, neonatal, and public health teams.

The clinical presentation is often subtle. Some affected newborns appear well at delivery, while others develop respiratory distress, hepatosplenomegaly, jaundice, anemia, thrombocytopenia, rash, bone abnormalities, or rhinitis. Because a normal examination does not exclude infection, assessment must combine maternal history, prenatal records, serology, treatment timing, neonatal findings, and follow-up reliability.

Current practice emphasizes earlier detection, repeat testing during pregnancy, rapid treatment with penicillin, and clear newborn risk classification. The goal is to prevent infection before birth whenever possible and to ensure that exposed infants receive timely evaluation and therapy when maternal treatment was absent, incomplete, or inadequately documented.

Why Congenital Infection Still Occurs

Transmission risk is greatest when the pregnant patient has primary or secondary syphilis, stages associated with high circulating treponemal burden. Infection can still pass to the fetus during latent disease, particularly when the infection is recent or untreated. The risk also depends on gestational age, maternal immune response, organism burden, and whether effective treatment was completed before delivery.

Several healthcare gaps contribute to continuing cases. These include missed prenatal care, delayed access to testing, failure to recognize a new infection after an early negative screen, incomplete documentation of treatment, and loss to follow-up. Reinfection can occur when a sexual partner is untreated, so partner services and repeat maternal testing are essential parts of prevention.

Prenatal care should also address the wider health context. Conditions that complicate pregnancy may affect appointment continuity, medication decisions, and fetal monitoring; a practical discussion of maternal autoimmune conditions can help clinicians frame infection prevention within coordinated maternal care rather than treating syphilis screening as an isolated task.

Screening During Pregnancy And Delivery

All pregnant patients should receive syphilis serologic screening at the first prenatal visit. The usual laboratory approach combines a nontreponemal test, such as rapid plasma reagin (RPR) or Venereal Disease Research Laboratory (VDRL) testing, with a treponemal assay. Some laboratories use a reverse-sequence algorithm, beginning with a treponemal immunoassay and resolving discordant results with a quantitative nontreponemal test and, when necessary, a second treponemal test.

Repeat screening at approximately 28 weeks and at delivery is recommended for patients in jurisdictions with high congenital syphilis rates or for those with increased risk. Risk factors include a new sex partner, multiple partners, a partner with syphilis, substance use, unstable housing, limited prenatal care, incarceration, and residence in a community with rising infection rates. Local public health guidance may call for universal third-trimester and delivery testing.

A delivery assessment is particularly important when prenatal records are missing or maternal risk has changed. No newborn should leave the hospital without documented maternal syphilis status from the current pregnancy. A reactive result requires rapid review of prior titers, disease stage, treatment dates, medication, partner management, and evidence of reinfection.

Maternal nutrition, substance exposure, and social conditions also influence prenatal engagement and infant outcomes. Broader prenatal counseling, including attention to maternal nutrition and epigenetic health, should complement—rather than replace—serologic screening and prompt antimicrobial therapy.

Interpreting Maternal Treatment

Benzathine penicillin G is the recommended treatment for syphilis during pregnancy, with the dose and schedule determined by disease stage. Penicillin is the only proven therapy that reliably treats maternal infection and prevents fetal congenital syphilis. If the patient has a documented penicillin allergy, desensitization followed by penicillin treatment is recommended; alternative antibiotics do not have comparable evidence for preventing fetal infection.

Treatment is considered adequate only when the regimen matches the stage of disease, the full course is completed, and there is sufficient time before delivery. For many clinical scenarios, therapy completed at least 30 days before delivery is used as an important benchmark. A lapse between scheduled weekly doses can require restarting the course, depending on the interval and regimen. Documentation should include product, dose, administration date, disease stage, and follow-up titers.

A fourfold change in the nontreponemal titer is clinically meaningful. A fourfold rise may indicate reinfection or treatment failure, while a fall after therapy supports an appropriate response but does not by itself determine whether the fetus or newborn was infected. Treponemal tests usually remain reactive for life and are not suitable for monitoring treatment response.

Newborn Evaluation And Risk Categories

Evaluation begins with comparison of the infant’s quantitative nontreponemal titer to the maternal titer at delivery, using the same test whenever possible. A neonatal titer at least fourfold higher than the maternal titer strongly supports congenital infection, but a lower or nonreactive result does not exclude it. IgM testing is not routinely relied upon because of variable performance and limited availability.

The physical examination should look for snuffles or persistent nasal discharge, rash involving the palms and soles, desquamation, hepatosplenomegaly, jaundice, generalized lymphadenopathy, edema, anemia, thrombocytopenia, skeletal tenderness, and neurologic abnormalities. Bone changes, abnormal liver function, and respiratory disease can occur even when the infant initially seems stable.

Management is usually grouped into practical categories:

These categories are frameworks rather than substitutes for specialist judgment. A neonate with symptoms, a high titer, an abnormal cerebrospinal fluid result, or unreliable follow-up should be managed conservatively. Consultation with pediatric infectious disease and public health specialists is appropriate when maternal records are unclear or findings do not fit a single category.

Penicillin Regimens And Safety

For proven or possible congenital infection, aqueous crystalline penicillin G is administered intravenously for 10 days. A commonly used schedule is 50,000 units/kg per dose every 12 hours during the first seven days of life and every eight hours thereafter, with adjustments for postnatal age and clinical circumstances. Procaine penicillin G, 50,000 units/kg by intramuscular injection once daily for 10 days, is an accepted alternative when intravenous administration is not practical.

If more than one day of a ten-day course is missed, the entire course generally must be restarted. This requirement makes discharge planning and medication administration records particularly important. A single-dose benzathine penicillin regimen is reserved for carefully selected lower-risk situations and should not be used when evaluation is abnormal, maternal treatment was inadequate, or congenital infection is clinically suspected.

A Jarisch–Herxheimer reaction can occur after therapy. Fever, irritability, tachycardia, transient respiratory worsening, or uterine contractions may develop within the first 24 hours. This inflammatory response is not an allergic reaction and should not lead to discontinuation of penicillin. Newborns who become unstable require standard supportive care and evaluation for other causes of deterioration.

Penicillin allergy is exceptionally uncommon in newborns, and there is no validated alternative that provides equivalent protection against congenital infection. When allergy is suspected in the pregnant patient, formal assessment and desensitization are safer than substituting an unproven drug. Neonatal treatment decisions should involve specialists when a serious reaction history is reported.

Follow-Up After Discharge

Every treated or exposed infant needs a documented follow-up plan before leaving the hospital. Quantitative RPR or VDRL testing is generally repeated every two to three months until the result becomes nonreactive or shows the expected decline. Testing should use the same method and, when possible, the same laboratory to make serial comparison more reliable.

An untreated infant with a reactive nontreponemal test should show a declining titer by three months and become nonreactive by six months if the result represented passive transfer of maternal antibody. Persistent reactivity at six months suggests infection and requires specialist evaluation. Treated infants are commonly reassessed at six, 12, and 18 months, depending on their initial findings and local protocols.

Treponemal antibodies transferred from the mother may persist for many months, so treponemal tests are not useful for determining early treatment response. Infants with abnormal cerebrospinal fluid findings may need repeat lumbar puncture and additional management. Hearing, vision, neurologic development, growth, and bone health should be monitored when clinical disease was present.

Public health reporting and partner treatment help prevent reinfection during the same pregnancy and reduce future congenital cases. A coordinated handoff between the maternity unit, neonatal service, primary care clinician, infectious disease team, laboratory, and public health department is often the difference between a documented plan and effective long-term follow-up.

Actions For Safer Perinatal Care

• Test for syphilis at the first prenatal visit and repeat testing at 28 weeks and delivery when risk or local prevalence warrants it.
• Verify maternal treatment stage, dose, timing, adherence, follow-up titers, and partner management rather than relying on a general statement that treatment was completed.
• Compare the newborn’s quantitative RPR or VDRL result with the maternal delivery titer and perform a careful examination for subtle congenital findings.
• Use a complete ten-day penicillin regimen when congenital infection is proven, highly probable, or cannot be safely excluded.
• Arrange serial serologic follow-up before discharge and involve public health or infectious disease specialists when records, testing, or follow-up are uncertain.

Congenital syphilis prevention depends on reliable systems at every transition: prenatal screening, rapid maternal treatment, delivery documentation, neonatal risk assessment, medication completion, and post-discharge surveillance. Perinatal teams can translate these updates into local protocols, standing order sets, and discharge checklists that make the correct action easier to deliver consistently. Reviewing current national guidance and reporting suspected cases promptly strengthens protection for newborns and future pregnancies.